Clinical Trial Update: Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W) [Phase 3]

View source ↗

Summary

The ACTIVE W Phase 3 trial evaluating clopidogrel with irbesartan for prevention of vascular events in atrial fibrillation has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• Irbesartan (irbesartan)

Snippet

Sponsor: Sanofi | Conditions: Atrial Fibrillation, Vascular Risk | Phase 3 | Status: TERMINATED